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dogrel (300 mg) followed by a daily dose of 75 mg for a
minimum of 6 weeks (2). We further justify this anticoag-
ulation regimen by the relative state of hypercoagulation we
have previously described, which follows off-pump coronary
artery bypass surgery (3). Because of variation on conduit
size as well as distal runoff, we no longer routinely use the
gray (4.5 to 5.0 mm) or green (5.0 to 5.5 mm) connectors
but limit our practice to the blue (5.5 to 6.0 mm) and purple
(6.0 to 7.0 mm) devices.
The authors do note that the published incidence of
saphenous vein graft failure using conventional suture tech-
nique at one year is 15%. Their reported incidence of graft
occlusion with this Food and Drug Administration-
approved product is one-fifth of this value. It is also
interesting to note that in those patients with early graft
occlusion, the phenomenon occurred in all grafts. This
observation may simply represent poor quality conduit, poor
distal runoff, hypercoagulation, or all of the above.
We continue to employ the symmetry device in our
surgical practice using the aforementioned protocol. There
is no doubt that use of the connector avoids the significant
manipulation of the ascending thoracic aorta so often
associated with catastrophic cerebral vascular accidents.
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REPLY
We agree that device size may account for some cases of
anastomotic device failure, although these data became
available only this month (February 2004), showing a
20.8%, 8.5%, 14.7%, and 0.0% failure rate in gray, green,
blue, and purple sizes, respectively, although these were not
statistically different from each other (1). In our report (2),
mostly green or blue devices were used, but after appreci-
ating that some patients were developing anastomotic device
stenosis, only blue and purple were used. The quality of the
veins and distal targets was felt to be adequate. In addition,
all occlusions were at the proximal anastomoses, rendering
poor distal runoff or technical problems with the distal
anastomosis less likely. All patients received aspirin 325 mg
and clopidogrel 75 mg on the day of the surgery. The aspirin
was given indefinitely, and the clopidogrel was continued
for two to three months.
Although the historical incidence of graft failure is higher
than in our report, our study was a clinical and not an
angiographic study. Thus, we did not evaluate the true
incidence, which is likely underestimated. In addition to the
studies pointed out in our study, a recent angiographic
(three month) report shows that 11%, 5%, and 7% of grafts
were either occluded, had 50% stenosis or 50% stenosis,
respectively (19 of 81, or 23% saphenous vein graft [SVG])
(1). Of note, 18.6% of patients had recurrent cardiac
symptoms, including three cardiac deaths. We have also
identified an additional three patients and six SVGs with
variable amounts of anastomotic device stenosis or occlusion
in whom coronary artery bypass graft was performed in
2002, the time period reported in our article. Two patients
were treated with sirolimus-eluting stents (2 SVGs and
native left circumflex obtuse marginal coronary artery, re-
spectively), and the other with medical therapy.
An important clinical consequence of anastomotic device
stenosis is its aggressive nature, which appears diffuse and
severe with involvement of all SVGs. This is in contrast to
in-stent restenosis, which is more variable and only rarely
leads to involvement of all stents. In this regard, patients
with anastomotic device stenosis can present with global
ischemic episodes that lead to myocardial infarction and
death, which is also unusual with coronary in-stent reste-
nosis. With the publication of additional reports describing
anastomotic device stenosis (1,3), we would reemphasize
increased oversight by regulatory agencies and adequately
powered, randomized controlled trials of such devices,
similar to coronary stent trials.
We believe that these devices will ultimately find their
niche in clinical practice, as the imperative to reduce stroke
during coronary artery bypass grafting is obviously critically
important and has been reflected by the rapid acceptance of
such devices by cardiovascular surgeons. However, improve-
ments in the design of such devices seem to be required to
improve outcomes (i.e., anti-proliferative drug coatings,
improved loading and deliverability, and so forth). Pending
further studies showing long-term efficacy, we continue to
advise limiting their use to patients with a clearly increased
risk of stroke during aortic cross-clamping. In patients in
whom the device needs to be placed, the use of the largest
devices, prolonged dual anti-platelet agents, careful follow-
up, communication between cardiothoracic surgeons and
cardiologists when the device is implanted, and ischemia
testing in the first two to six months are warranted. The
treatment of anastomotic device stenosis will continue to
evolve as we learn more about this new iatrogenic disease.
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Optimal Target International
Normalized Ratio For Patients
With Mechanical Heart Valves
Vink et al. (1) compared the occurrence rates of bleeding
and thrombo-embolism among patients with mechanical
heart valves who had either high-intensity or low-intensity
vitamin K antagonist therapy (VKA). Based on their find-
ings of lower combined bleeding and thrombo-embolic
occurrence rates in the high- versus low-intensity VKA
group, they concluded that “both aortic and mitral valves
will benefit from a treatment strategy with a target INR
higher than 3.0.” This is a controversial conclusion because
most recent publications recommend a valve-specific and
lower target international normalized ratio (INR) (2,3).
Therefore, we closely studied Vink’s analyses and have the
following comments.
When trying to identify the optimal target INR for
patients with mechanical heart valves, not only the occur-
rence rates of bleeding and thrombo-embolism but also the
consequences of these events need to be considered. It may
well be possible that although the combined occurrence
rates of bleeding and thrombo-embolism are lower in the
high-intensity VKA group, the combined mortality associ-
ated with bleeding and thromboembolism is lower in the
low-intensity VKA group.
We repeated the reported meta-analysis for the aortic
valve replacement group, and we pooled the mortality rates
of bleeding and thrombo-embolism from those studies that
reported on mortality resulting from these events (11 of the
21 studies in the low-intensity and 5 of the 9 studies in the
high-intensity VKA group). We found in the low-intensity
VKA group versus the high-intensity VKA group, a pooled
mortality rate for bleeding of 12% (95% confidence interval
[CI] 7.7% to 16.3%) versus 20% (95% CI 13.3% to 26.6%;
p  0.05), for valve thrombosis 27% (95% CI 12% to 42%)
versus 33% (95% CI 3.5% to 63.5% p  NS), and for
thrombo-embolism 14% (95% CI 9.6% to 18.4%) versus
14% (95% CI 8.3% to 19.7% p  NS). We entered the
occurrence rates and mortality rates of bleeding, valve
thrombosis, and thrombo-embolism from the meta-analysis
in a microsimulation model that we previously developed (4)
to estimate patient prognosis after aortic valve replacement
with mechanical prostheses, and we simulated 10,000 life
histories of a 56-year-old (mean age in meta-analysis) male
patient after aortic valve replacement in order to estimate
the expected lifetime risk of death due to bleeding, valve
thrombosis, and thrombo-embolism for either a low-
intensity or high-intensity anticoagulation regimen. We
found that the combined lifetime risk of death due to
bleeding, valve thrombosis, and thrombo-embolism in the
low-intensity versus the high-intensity VKA group was
6.3% versus 7.8% (p  NS). This shows that, when
considering the mortality due to bleeding and thrombo-
embolic events, for aortic valve patients nothing is gained by
a target INR higher than 3.0.
In conclusion, a meta-analysis of only bleeding and
thrombo-embolic event rates is methodologically insuffi-
cient to determine the optimal anticoagulation regimen for
patients with mechanical heart valves. Modelling techniques
are essential to evaluate the burden of the competing risks of
bleeding and thrombo-embolism and their consequences
during the lifetime of the patient.
Johanna J. M. Takkenberg, MD, PhD
John P. A. Puvimanasinghe, MD
Lex A. van Herwerden, MD, PhD
Erasmus University Medical Center
Dept. of Cardio-Thoracic Surgery, Bd162
P.O. Box 2040
3000CA Rotterdam
The Netherlands
E-mail: j.j.m.takkenberg@erasmusmc.nl
doi:10.1016/j.jacc.2004.06.010
REFERENCES
1. Vink R, Kraaijenhagen RA, Hutten BA, et al. The optimal intensity of
vitamin K antagonists in patients with mechanical heart valves: a
meta-analysis. J Am Coll Cardiol 2003;42:2042–8.
2. Huth C, Friedl A, Rost A. Intensity of oral anticoagulation after
implantation of St. Jude Medical aortic prosthesis: analysis of the
GELIA database (GELIA 4). Eur Heart J Suppl 2001;Suppl
Q:Q33–8.
1142 Letters to the Editor JACC Vol. 44, No. 5, 2004
September 1, 2004:1139–45
